English Spanish Chinese Russian German French Japanese Hindi Telugu Tamil

Arquivos de Medicina

  • ISSN: 1989-5216
  • Índice h do diário: 22
  • Pontuação de citação de diário: 4.96
  • Fator de impacto do periódico: 4.44
Indexado em
  • Genamics JournalSeek
  • Infraestrutura Nacional de Conhecimento da China (CNKI)
  • Diretório de Indexação de Periódicos de Pesquisa (DRJI)
  • OCLC- WorldCat
  • Invocação Proquest
  • publons
  • Fundação de Genebra para Educação e Pesquisa Médica
  • Euro Pub
  • Google Scholar
  • Laboratórios secretos do mecanismo de pesquisa
Veja mais
Compartilhe esta página

Abstrato

Comparative Analysis of Biochemical Indexes of Severe and Non-Severe Patients Infected with COVID-19

Boufrioua E*, Awati E, Ouahidi I, Elomari L, Ouassif H, Arsalane L and Boukhira A

Background: The coronavirus disease 19 (COVID-19) is a highly transmittable and pathogenic viral infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The characteristics of laboratory findings of coronavirus are of great significance for clinical diagnosis and treatment. This study aimed to evaluate the accuracy of biochemical parameters in COVID-19 and to compare them according to the severity of the disease.

Methods: This diagnostic accuracy study was conducted in COVID-19 patients, During the study period 169 COVID-19 patients were hospitalized at the Avicenne military hospital, 20 patients in the medical intensive care unit (severe group) and 149 patients in the COVID-19 isolation hospital (non-severe group).

Results: Through the analysis of laboratory data of patients with COVID-19 (169 patients), we demonstrated that severe cases possessed higher levels of C-Reactive Protein (CRP), Aspartate Aminotransferase(AST), Alanine Aminotransferase (ALT), and Urea levels in serum, creatinine, hypoalbuminemia, hyponatremia, hyperbilirubinemia, troponin, procalcitonin.

Conclusion: The analysis of the current scientific literature demonstrates the value of laboratory parameters as simple, rapid, and cost-effective biomarkers in COVID-19 patients.